Resitu: minimally invasive surgical technology

New seed round

Resitu Medical has closed the second seed round of 1,5 MEUR mainly by existing shareholders. Major shareholders are Novoaim 60%, ALMI Invest 15% and Stockholm Business Angels (STOAF) 15%.

The development of the first instrument is proceeding according to plan. The product design is finalized and is currently being transferred to production. “The funding will be used to verification, validation, clinical studies, and prepare the documentation for CE mark and FDA submission” says CEO Stefan Sowa.

Published 2022-09-19


Resitu Medical AB
Rapsgatan 7B
Uppsala, Sweden

Resitu Medical AB is a Swedish Medical Device company founded in 2019. The company is developing instruments enabling safe removal of intact tissues by a revolutionary technology. The solution has the potential to create a paradigm shift in the management of breast cancer. The portfolio of instruments will speed up the process of cancer management using a minimally invasive approach and facilitating the way radiologists and surgeons work.

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively.